Investigational Medical Therapies for Endometriosis: Current Data and Future Trends

Shahryar K. Kavoussi; Ran Zhang; Dan I. Lebovic

doi:10.1055/s-0037-1604095

Investigational Medical Therapies for Endometriosis: Current Data and Future Trends

Shahryar K. Kavoussi, Ran Zhang, Dan I. Lebovic

Division of Reproductive Endocrinology & Infertility

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Current mainstays of medical therapy for endometriosis preclude fertility or may have unwanted side effects. Therefore, research has been underway to find alternatives to current options which may be applied to future medical treatment. The focus of this review is that of investigational hormonal and nonhormonal medical therapies based on in vitro and in vivo animal models of endometriosis as well as in human endometrial and endometriotic cells in vitro. Assessment of the safety and efficacy of such novel medical treatments have been, and continue to be, necessary prior to clinical trials.

Original language	English
Pages (from-to)	318-325
Number of pages	8
Journal	Seminars in Reproductive Medicine
Volume	35
Issue number	4
DOIs	https://doi.org/10.1055/s-0037-1604095
State	Published - Jul 1 2017

Keywords

aromatase inhibitor
endometriosis
GnRH antagonist
TNFα inhibitor
VEGF

Access to Document

10.1055/s-0037-1604095

Cite this

@article{20392cf2f7ab42e6a7724fd50e03967e,

title = "Investigational Medical Therapies for Endometriosis: Current Data and Future Trends",

abstract = "Current mainstays of medical therapy for endometriosis preclude fertility or may have unwanted side effects. Therefore, research has been underway to find alternatives to current options which may be applied to future medical treatment. The focus of this review is that of investigational hormonal and nonhormonal medical therapies based on in vitro and in vivo animal models of endometriosis as well as in human endometrial and endometriotic cells in vitro. Assessment of the safety and efficacy of such novel medical treatments have been, and continue to be, necessary prior to clinical trials.",

keywords = "aromatase inhibitor, endometriosis, GnRH antagonist, TNFα inhibitor, VEGF",

author = "Kavoussi, \{Shahryar K.\} and Ran Zhang and Lebovic, \{Dan I.\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2017 by Thieme Medical Publishers, Inc.",

year = "2017",

month = jul,

day = "1",

doi = "10.1055/s-0037-1604095",

language = "English",

volume = "35",

pages = "318--325",

journal = "Seminars in Reproductive Medicine",

issn = "1526-8004",

number = "4",

}

TY - JOUR

T1 - Investigational Medical Therapies for Endometriosis

T2 - Current Data and Future Trends

AU - Kavoussi, Shahryar K.

AU - Zhang, Ran

AU - Lebovic, Dan I.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Current mainstays of medical therapy for endometriosis preclude fertility or may have unwanted side effects. Therefore, research has been underway to find alternatives to current options which may be applied to future medical treatment. The focus of this review is that of investigational hormonal and nonhormonal medical therapies based on in vitro and in vivo animal models of endometriosis as well as in human endometrial and endometriotic cells in vitro. Assessment of the safety and efficacy of such novel medical treatments have been, and continue to be, necessary prior to clinical trials.

AB - Current mainstays of medical therapy for endometriosis preclude fertility or may have unwanted side effects. Therefore, research has been underway to find alternatives to current options which may be applied to future medical treatment. The focus of this review is that of investigational hormonal and nonhormonal medical therapies based on in vitro and in vivo animal models of endometriosis as well as in human endometrial and endometriotic cells in vitro. Assessment of the safety and efficacy of such novel medical treatments have been, and continue to be, necessary prior to clinical trials.

KW - aromatase inhibitor

KW - endometriosis

KW - GnRH antagonist

KW - TNFα inhibitor

KW - VEGF

UR - https://www.scopus.com/pages/publications/85031726756

U2 - 10.1055/s-0037-1604095

DO - 10.1055/s-0037-1604095

M3 - Article

C2 - 29036739

AN - SCOPUS:85031726756

SN - 1526-8004

VL - 35

SP - 318

EP - 325

JO - Seminars in Reproductive Medicine

JF - Seminars in Reproductive Medicine

IS - 4

ER -

Investigational Medical Therapies for Endometriosis: Current Data and Future Trends

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this